NASDAQ:ALVR

AlloVir Competitors

$22.76

-0.45 (-1.94 %)

(As of 04/12/2021 05:20 PM ET)

Add

Compare

Today's Range

$21.70

Now: $22.76▼

$23.49

50-Day Range

$20.81

MA: $29.84▼

$41.61

52-Week Range

$18.15

Now: $22.76▼

$48.96

Volume347,804 shs

Average Volume369,727 shs

Market Capitalization$1.48 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

AlloVir (NASDAQ:ALVR) Vs. ADPT, KOD, VIR, CBPO, ALLO, and IOVA

Should you be buying ALVR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to AlloVir, including Adaptive Biotechnologies (ADPT), Kodiak Sciences (KOD), Vir Biotechnology (VIR), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), and Iovance Biotherapeutics (IOVA).

AlloVir vs. Adaptive Biotechnologies Stock

Adaptive Biotechnologies (NASDAQ:ADPT) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Adaptive Biotechnologies and AlloVir, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	0	2	4	0	2.67
AlloVir	0	0	4	0	3.00

Adaptive Biotechnologies currently has a consensus price target of $61.40, indicating a potential upside of 52.85%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 114.19%. Given AlloVir's stronger consensus rating and higher probable upside, analysts clearly believe AlloVir is more favorable than Adaptive Biotechnologies.

Institutional and Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 1.0% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Adaptive Biotechnologies and AlloVir's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-132.32%	-20.15%	-13.09%
AlloVir	N/A	N/A	N/A

Earnings & Valuation

This table compares Adaptive Biotechnologies and AlloVir's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$85.07 million	65.74	$-68,610,000.00	($1.01)	-39.77
AlloVir	N/A	N/A	N/A	N/A	N/A

AlloVir has lower revenue, but higher earnings than Adaptive Biotechnologies.

Summary

AlloVir beats Adaptive Biotechnologies on 5 of the 8 factors compared between the two stocks.

AlloVir vs. Kodiak Sciences Stock

Kodiak Sciences (NASDAQ:KOD) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Kodiak Sciences and AlloVir, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1	7	4	0	2.25
AlloVir	0	0	4	0	3.00

Kodiak Sciences currently has a consensus price target of $129.9091, indicating a potential upside of 22.32%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 114.19%. Given AlloVir's stronger consensus rating and higher probable upside, analysts clearly believe AlloVir is more favorable than Kodiak Sciences.

Institutional and Insider Ownership

82.3% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 39.3% of Kodiak Sciences shares are owned by insiders. Comparatively, 1.0% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Kodiak Sciences and AlloVir's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	$-47,370,000.00	($1.25)	-84.96
AlloVir	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Kodiak Sciences and AlloVir's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-32.32%	-23.86%
AlloVir	N/A	N/A	N/A

Summary

AlloVir beats Kodiak Sciences on 4 of the 6 factors compared between the two stocks.

AlloVir vs. Vir Biotechnology Stock

Vir Biotechnology (NASDAQ:VIR) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and price targets for Vir Biotechnology and AlloVir, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	2	0	5	0	2.43
AlloVir	0	0	4	0	3.00

Vir Biotechnology presently has a consensus price target of $66.00, indicating a potential upside of 53.06%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 114.19%. Given AlloVir's stronger consensus rating and higher probable upside, analysts clearly believe AlloVir is more favorable than Vir Biotechnology.

Institutional & Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by company insiders. Comparatively, 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Vir Biotechnology and AlloVir's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$8.09 million	682.16	$-174,680,000.00	($5.76)	-7.49
AlloVir	N/A	N/A	N/A	N/A	N/A

AlloVir has lower revenue, but higher earnings than Vir Biotechnology.

Profitability

This table compares Vir Biotechnology and AlloVir's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-339.61%	-47.11%	-39.44%
AlloVir	N/A	N/A	N/A

Summary

AlloVir beats Vir Biotechnology on 5 of the 9 factors compared between the two stocks.

AlloVir vs. China Biologic Products Stock

China Biologic Products (NASDAQ:CBPO) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and price targets for China Biologic Products and AlloVir, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Biologic Products	0	0	0	0	N/A
AlloVir	0	0	4	0	3.00

AlloVir has a consensus price target of $48.75, indicating a potential upside of 114.19%. Given AlloVir's higher probable upside, analysts clearly believe AlloVir is more favorable than China Biologic Products.

Institutional & Insider Ownership

34.8% of China Biologic Products shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 2.7% of China Biologic Products shares are owned by company insiders. Comparatively, 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares China Biologic Products and AlloVir's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Biologic Products	$503.70 million	9.26	$138.81 million	$4.28	27.69
AlloVir	N/A	N/A	N/A	N/A	N/A

China Biologic Products has higher revenue and earnings than AlloVir.

Profitability

This table compares China Biologic Products and AlloVir's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
China Biologic Products	27.43%	8.32%	7.64%
AlloVir	N/A	N/A	N/A

Summary

China Biologic Products beats AlloVir on 6 of the 8 factors compared between the two stocks.

AlloVir vs. Allogene Therapeutics Stock

Allogene Therapeutics (NASDAQ:ALLO) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Earnings and Valuation

This table compares Allogene Therapeutics and AlloVir's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	N/A	N/A	$-184,590,000.00	($1.83)	-16.16
AlloVir	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and price targets for Allogene Therapeutics and AlloVir, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	0	3	13	0	2.81
AlloVir	0	0	4	0	3.00

Allogene Therapeutics presently has a consensus price target of $52.0833, indicating a potential upside of 76.08%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 114.19%. Given AlloVir's stronger consensus rating and higher probable upside, analysts clearly believe AlloVir is more favorable than Allogene Therapeutics.

Profitability

This table compares Allogene Therapeutics and AlloVir's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-27.59%	-24.97%
AlloVir	N/A	N/A	N/A

Institutional & Insider Ownership

59.9% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 31.3% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

AlloVir beats Allogene Therapeutics on 4 of the 7 factors compared between the two stocks.

AlloVir vs. Iovance Biotherapeutics Stock

AlloVir (NASDAQ:ALVR) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Earnings & Valuation

This table compares AlloVir and Iovance Biotherapeutics' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	N/A	N/A	N/A
Iovance Biotherapeutics	N/A	N/A	$-197,560,000.00	($1.59)	-18.50

Analyst Ratings

This is a breakdown of current recommendations for AlloVir and Iovance Biotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0	0	4	0	3.00
Iovance Biotherapeutics	0	1	9	0	2.90

AlloVir presently has a consensus target price of $48.75, indicating a potential upside of 114.19%. Iovance Biotherapeutics has a consensus target price of $50.50, indicating a potential upside of 71.71%. Given AlloVir's stronger consensus rating and higher probable upside, analysts plainly believe AlloVir is more favorable than Iovance Biotherapeutics.

Profitability

This table compares AlloVir and Iovance Biotherapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	N/A	N/A
Iovance Biotherapeutics	N/A	-50.64%	-45.64%

Institutional & Insider Ownership

32.1% of AlloVir shares are held by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are held by institutional investors. 1.0% of AlloVir shares are held by insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

AlloVir beats Iovance Biotherapeutics on 4 of the 7 factors compared between the two stocks.